ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board
August 05 2020 - 2:09PM
- Dr. Sofia is an Inductee in the American Chemical
Society Medicinal Chemistry Hall of Fame
- ViralClear Pharmaceuticals is Currently in Phase 2
Trials with Merimepodib in the Fight Against
COVID-19
BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the
“Company”) subsidiary, ViralClear Pharmaceuticals, Inc.
(ViralClear), today announced the addition of Dr. Michael J. Sofia
to its Scientific Advisory Board (SAB).
Michael Sofia, Ph.D., has introduced numerous drugs into
clinical development for the treatment of infectious diseases and
inflammatory diseases. He has authored over 110 publications, 15
book chapters and is an inventor on more than 54 US patents.
He is the principal inventor of sofosbuvir, currently
marketed as the backbone of hepatitis C curative therapies
Sovaldi(R), Harvoni(R), Epclusa(R) and Vosevi(R). Dr. Sofia
has received numerous recognitions, including the 2016
Lasker-Debakey Award in Clinical Medical Research and induction in
the American Chemical Society Medicinal Chemistry Hall of Fame.
Currently, Dr. Sofia is a Co-founder and Chief Scientific Officer
of Arbutus Biopharma, Inc., a company focused on the discovery and
development of therapies to cure hepatitis B.
“With Mike’s addition to our Scientific Advisory Board, we
believe that we have a very well rounded group of experts who can
provide ViralClear with guidance on how to best proceed in
addressing the current COVID-19 pandemic and other significant
viral infections of special interest,” stated Jerome B. Zeldis,
M.D., Ph.D., the acting Chief Medical Officer and Head of
ViralClear Pharmaceuticals, Inc.
Dr. Sofia commented, “I am excited to join the Scientific
Advisory Board of ViralClear. The COVID-19 pandemic has called the
drug development community to action to find therapies that can
combat this disease. ViralClear’s merimepodib is a novel agent with
a new mechanism of action that has the potential to help address
this pandemic now. I am eager to bring my expertise in antiviral
drug development to help ViralClear in its efforts to develop
merimepodib for the fight against COVID-19.”
ViralClear recently announced the formation of its Scientific
Advisory Board. The goal of the SAB is to review all aspects of
drug discovery and development and advise ViralClear on its mission
to control emerging infections and viral diseases of special
interest, including COVID-19. Robin Robinson, Ph.D., the former
Head of Biomedical Advanced Research and Development Authority
(BARDA), and J. Paul Waymack, M.D., ScD, formerly of the Food and
Drug Administration, were the first advisors appointed to the
SAB.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Merimepodib and ViralClear
BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary,
ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to
develop a novel pharmaceutical called merimepodib to treat patients
with COVID-19. Merimepodib is intended to be orally administered,
and has demonstrated broad-spectrum in vitro antiviral activity,
including strong activity against SARS-CoV-2 in cell cultures.
Merimepodib was previously in development as a treatment for
chronic hepatitis C and psoriasis by Vertex Pharmaceuticals
Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5
in phase 2) with over 400 subjects and patients and an extensive
preclinical safety package was completed.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024